Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice

Jung Eun Kim, Mi Hwa Lee, Deok Hwa Nam, Hye Kyoung Song, Young Sun Kang, Ji Eun Lee, Hyun Wook Kim, Jin Joo Cha, Young Youl Hyun, Sang Youb Han, Kum Hyun Han, Jee Young Han, Dae-Ryong Cha

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The NF-κB pathway plays an important role in chronic inflammatory and autoimmune diseases. Recently, NF-κB has also been suggested as an important mechanism linking obesity, inflammation, and metabolic disorders. However, there is no current evidence regarding the mechanism of action of NF-κB inhibition in insulin resistance and diabetic nephropathy in type 2 diabetic animal models. We investigated the effects of the NF-κB inhibitor celastrol in db/db mice. The treatment with celastrol for 2 months significantly lowered fasting plasma glucose (FPG), HbA1C and homeostasis model assessment index (HOMA-IR) levels. Celastrol also exhibited significant decreases in body weight, kidney/body weight and adiposity. Celastrol reduced insulin resistance and lipid abnormalities and led to higher plasma adiponectin levels. Celastrol treatment also significantly mitigated lipid accumulation and oxidative stress in organs including the kidney, liver and adipose tissue. The treated group also exhibited significantly lower creatinine levels and urinary albumin excretion was markedly reduced. Celastrol treatment significantly lowered mesangial expansion and suppressed type IV collagen, PAI-1 and TGFβ1 expressions in renal tissues. Celastrol also improved abnormal lipid metabolism, oxidative stress and proinflammatory cytokine activity in the kidney. In cultured podocytes, celastrol treatment abolished saturated fatty acid-induced proinflammatory cytokine synthesis. Taken together, celastrol treatment not only improved insulin resistance, glycemic control and oxidative stress, but also improved renal functional and structural changes through both metabolic and anti-inflammatory effects in the kidney. These results suggest that targeted therapy for NF-κB may be a useful new therapeutic approach for the management of type II diabetes and diabetic nephropathy.

Original languageEnglish
Article numbere62068
JournalPLoS One
Volume8
Issue number4
DOIs
Publication statusPublished - 2013 Apr 26

Fingerprint

insulin resistance
Insulin Resistance
kidneys
Insulin
Kidney
mice
Wounds and Injuries
diabetic nephropathy
Oxidative stress
oxidative stress
Oxidative Stress
cytokines
Diabetic Nephropathies
therapeutics
glycemic control
adiponectin
body weight
autoimmune diseases
metabolic diseases
adiposity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice. / Kim, Jung Eun; Lee, Mi Hwa; Nam, Deok Hwa; Song, Hye Kyoung; Kang, Young Sun; Lee, Ji Eun; Kim, Hyun Wook; Cha, Jin Joo; Hyun, Young Youl; Han, Sang Youb; Han, Kum Hyun; Han, Jee Young; Cha, Dae-Ryong.

In: PLoS One, Vol. 8, No. 4, e62068, 26.04.2013.

Research output: Contribution to journalArticle

Kim, JE, Lee, MH, Nam, DH, Song, HK, Kang, YS, Lee, JE, Kim, HW, Cha, JJ, Hyun, YY, Han, SY, Han, KH, Han, JY & Cha, D-R 2013, 'Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice', PLoS One, vol. 8, no. 4, e62068. https://doi.org/10.1371/journal.pone.0062068
Kim, Jung Eun ; Lee, Mi Hwa ; Nam, Deok Hwa ; Song, Hye Kyoung ; Kang, Young Sun ; Lee, Ji Eun ; Kim, Hyun Wook ; Cha, Jin Joo ; Hyun, Young Youl ; Han, Sang Youb ; Han, Kum Hyun ; Han, Jee Young ; Cha, Dae-Ryong. / Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice. In: PLoS One. 2013 ; Vol. 8, No. 4.
@article{12997fe1399f4921a611aa47e18c1456,
title = "Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice",
abstract = "The NF-κB pathway plays an important role in chronic inflammatory and autoimmune diseases. Recently, NF-κB has also been suggested as an important mechanism linking obesity, inflammation, and metabolic disorders. However, there is no current evidence regarding the mechanism of action of NF-κB inhibition in insulin resistance and diabetic nephropathy in type 2 diabetic animal models. We investigated the effects of the NF-κB inhibitor celastrol in db/db mice. The treatment with celastrol for 2 months significantly lowered fasting plasma glucose (FPG), HbA1C and homeostasis model assessment index (HOMA-IR) levels. Celastrol also exhibited significant decreases in body weight, kidney/body weight and adiposity. Celastrol reduced insulin resistance and lipid abnormalities and led to higher plasma adiponectin levels. Celastrol treatment also significantly mitigated lipid accumulation and oxidative stress in organs including the kidney, liver and adipose tissue. The treated group also exhibited significantly lower creatinine levels and urinary albumin excretion was markedly reduced. Celastrol treatment significantly lowered mesangial expansion and suppressed type IV collagen, PAI-1 and TGFβ1 expressions in renal tissues. Celastrol also improved abnormal lipid metabolism, oxidative stress and proinflammatory cytokine activity in the kidney. In cultured podocytes, celastrol treatment abolished saturated fatty acid-induced proinflammatory cytokine synthesis. Taken together, celastrol treatment not only improved insulin resistance, glycemic control and oxidative stress, but also improved renal functional and structural changes through both metabolic and anti-inflammatory effects in the kidney. These results suggest that targeted therapy for NF-κB may be a useful new therapeutic approach for the management of type II diabetes and diabetic nephropathy.",
author = "Kim, {Jung Eun} and Lee, {Mi Hwa} and Nam, {Deok Hwa} and Song, {Hye Kyoung} and Kang, {Young Sun} and Lee, {Ji Eun} and Kim, {Hyun Wook} and Cha, {Jin Joo} and Hyun, {Young Youl} and Han, {Sang Youb} and Han, {Kum Hyun} and Han, {Jee Young} and Dae-Ryong Cha",
year = "2013",
month = "4",
day = "26",
doi = "10.1371/journal.pone.0062068",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice

AU - Kim, Jung Eun

AU - Lee, Mi Hwa

AU - Nam, Deok Hwa

AU - Song, Hye Kyoung

AU - Kang, Young Sun

AU - Lee, Ji Eun

AU - Kim, Hyun Wook

AU - Cha, Jin Joo

AU - Hyun, Young Youl

AU - Han, Sang Youb

AU - Han, Kum Hyun

AU - Han, Jee Young

AU - Cha, Dae-Ryong

PY - 2013/4/26

Y1 - 2013/4/26

N2 - The NF-κB pathway plays an important role in chronic inflammatory and autoimmune diseases. Recently, NF-κB has also been suggested as an important mechanism linking obesity, inflammation, and metabolic disorders. However, there is no current evidence regarding the mechanism of action of NF-κB inhibition in insulin resistance and diabetic nephropathy in type 2 diabetic animal models. We investigated the effects of the NF-κB inhibitor celastrol in db/db mice. The treatment with celastrol for 2 months significantly lowered fasting plasma glucose (FPG), HbA1C and homeostasis model assessment index (HOMA-IR) levels. Celastrol also exhibited significant decreases in body weight, kidney/body weight and adiposity. Celastrol reduced insulin resistance and lipid abnormalities and led to higher plasma adiponectin levels. Celastrol treatment also significantly mitigated lipid accumulation and oxidative stress in organs including the kidney, liver and adipose tissue. The treated group also exhibited significantly lower creatinine levels and urinary albumin excretion was markedly reduced. Celastrol treatment significantly lowered mesangial expansion and suppressed type IV collagen, PAI-1 and TGFβ1 expressions in renal tissues. Celastrol also improved abnormal lipid metabolism, oxidative stress and proinflammatory cytokine activity in the kidney. In cultured podocytes, celastrol treatment abolished saturated fatty acid-induced proinflammatory cytokine synthesis. Taken together, celastrol treatment not only improved insulin resistance, glycemic control and oxidative stress, but also improved renal functional and structural changes through both metabolic and anti-inflammatory effects in the kidney. These results suggest that targeted therapy for NF-κB may be a useful new therapeutic approach for the management of type II diabetes and diabetic nephropathy.

AB - The NF-κB pathway plays an important role in chronic inflammatory and autoimmune diseases. Recently, NF-κB has also been suggested as an important mechanism linking obesity, inflammation, and metabolic disorders. However, there is no current evidence regarding the mechanism of action of NF-κB inhibition in insulin resistance and diabetic nephropathy in type 2 diabetic animal models. We investigated the effects of the NF-κB inhibitor celastrol in db/db mice. The treatment with celastrol for 2 months significantly lowered fasting plasma glucose (FPG), HbA1C and homeostasis model assessment index (HOMA-IR) levels. Celastrol also exhibited significant decreases in body weight, kidney/body weight and adiposity. Celastrol reduced insulin resistance and lipid abnormalities and led to higher plasma adiponectin levels. Celastrol treatment also significantly mitigated lipid accumulation and oxidative stress in organs including the kidney, liver and adipose tissue. The treated group also exhibited significantly lower creatinine levels and urinary albumin excretion was markedly reduced. Celastrol treatment significantly lowered mesangial expansion and suppressed type IV collagen, PAI-1 and TGFβ1 expressions in renal tissues. Celastrol also improved abnormal lipid metabolism, oxidative stress and proinflammatory cytokine activity in the kidney. In cultured podocytes, celastrol treatment abolished saturated fatty acid-induced proinflammatory cytokine synthesis. Taken together, celastrol treatment not only improved insulin resistance, glycemic control and oxidative stress, but also improved renal functional and structural changes through both metabolic and anti-inflammatory effects in the kidney. These results suggest that targeted therapy for NF-κB may be a useful new therapeutic approach for the management of type II diabetes and diabetic nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=84876817513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876817513&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0062068

DO - 10.1371/journal.pone.0062068

M3 - Article

C2 - 23637966

AN - SCOPUS:84876817513

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e62068

ER -